GlassScriptPhysician profile
Susan Mayne
NPI 1114474368
$3,204.09
in general payments reported to CMS, 2019-2025
11 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,118 · 2022: $438 · 2023: $759 · 2024: $436 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,478.27 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,225.32 | 2021-2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $623.53 | 2023-2024 | Sotyktu |
| Abbvie INC. | $444.63 | 2021-2023 | |
| Lilly USA, LLC | $256.74 | 2021-2025 | Ebglyss, Olumiant |
| Ucb, INC. | $227.05 | 2021-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $114.22 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $104.26 | 2025 | |
| Janssen Biotech, INC. | $95.47 | 2021-2023 | Tremfya |
| Genzyme Corporation | $55.37 | 2024-2025 | |
| Galderma Laboratories, L.P. | $35.45 | 2023-2025 | Epsolay, Twyneo, Nemluvio |
| Organon LLC | $22.05 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Mayne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.